Journal of Blood Group Serology and Molecular Genetics Volume 33, Number 3, 2017 CONTENTS

Total Page:16

File Type:pdf, Size:1020Kb

Journal of Blood Group Serology and Molecular Genetics Volume 33, Number 3, 2017 CONTENTS Journal of Blood Group Serology and Molecular Genetics VOLUME 33, N UMBER 3, 2017 This issue of Immunohematology is supported by a contribution from Grifols Diagnostics Solutions, Inc. Dedicated to advancement and education in molecular and serologic immunohematology Immunohematology Journal of Blood Group Serology and Molecular Genetics Volume 33, Number 3, 2017 CONTENTS C ASE R EPO R T 99 ABO serology in a case of persistent weak A in a recipient following a group O–matched unrelated bone marrow transplant D.E. Grey, E.A. Fong, C. Cole, J. Jensen, and J. Finlayson O R IGINAL R EPO R T 105 Stability guidelines for dithiothreitol-treated red blood cell reagents used for antibody detection methods in patients treated with daratumumab W.L. Disbro C ASE R EPO R T 110 A LU:−16 individual with antibodies C. Éthier, C. Parent, A.-S. Lemay, N. Baillargeon, G. Laflamme, J. Lavoie, J. Perreault, and M. St-Louis C ASE R EPO R T 114 Postpartum acute hemolytic transfusion reactions associated with anti-Lea in two pregnancies complicated by preeclampsia M. Marchese O R IGINAL R EPO R T 119 Red blood cell phenotype prevalence in blood donors who self- identify as Hispanic C.A. Sheppard, N.L. Bolen, B. Eades, G. Ochoa-Garay, and M.H. Yazer R EVIEW 125 DEL Phenotype D.H. Kwon, S.G. Sandler, and W.A. Flegel 133 138 142 144 A NNOUN C EMENTS A DVE R TISEMENTS I NST R U C TIONS S UBS cr IPTION FO R A UTHO R S I NFO R M AT I O N E DITO R - IN -C HIEF E DITO R IAL B OA R D Sandra Nance, MS, MT(ASCP)SBB Philadelphia, Pennsylvania Patricia Arndt, MT(ASCP)SBB Geralyn M. Meny, MD Pomona, California San Antonio, Texas M ANAGING E DITO R Barbara J. Bryant, MD Paul M. Ness, MD Cynthia Flickinger, MT(ASCP)SBB Galveston, Texas Baltimore, Maryland Wilmington, Delaware Lilian M. Castilho, PhD Thierry Peyrard, PharmD, PhD Campinas, Brazil Paris, France TEC HNI C AL E DITO R S Christine Lomas-Francis, MSc Martha R. Combs, MT(ASCP)SBB S. Gerald Sandler, MD New York City, New York Durham, North Carolina Washington, District of Columbia Joyce Poole, FIBMS Geoffrey Daniels, PhD Ira A. Shulman, MD Bristol, United Kingdom Bristol, United Kingdom Los Angeles, California Dawn M. Rumsey, ART(CSMLT) Anne F. Eder, MD Jill R. Storry, PhD Washington, District of Columbia Lund, Sweden Norcross, Georgia Melissa R. George, DO, FCAP Nicole Thornton S ENIO R M EDI C AL E DITO R Hershey, Pennsylvania Bristol, United Kingdom David Moolten, MD Julie K. Karp, MD Philadelphia, Pennsylvania Philadelphia, Pennsylvania E ME R ITUS E DITO R S Jose Lima, MD Delores Mallory, MT(ASCP)SBB A SSO C I AT E M EDI C AL E DITO R S Douglassville, Georgia Supply, North Carolina P. Dayand Borge, MD Philadelphia, Pennsylvania Christine Lomas-Francis, MSc Marion E. Reid, PhD, FIBMS New York City, New York Bristol, United Kingdom Corinne L. Goldberg, MD Durham, North Carolina M OLEC ULA R E DITO R Margaret A. Keller, PhD Philadelphia, Pennsylvania Immunohematology is published quarterly (March, June, September, and December) by the E DITO R IAL A S S I S TA N T American Red Cross, National Headquarters, Washington, DC 20006. Linda Frazier Immunohematology is indexed and included in Index Medicus and MEDLINE on the MEDLARS system. The contents are also cited in the EBASE/Excerpta Medica and Elsevier P R ODU C TION A S S I S TA N T BIOBASE/Current Awareness in Biological Sciences (CABS) databases. Marge Manigly The subscription price is $50 for individual, $100 for institution (U.S.), and $60 for individual, $100 for institution (foreign), per year. C OPY E DITO R Subscriptions, Change of Address, and Extra Copies: Frederique Courard-Houri Immunohematology, P.O. Box 40325 Philadelphia, PA 19106 P R OOF R EADE R Wendy Martin-Shuma Or call (215) 451-4902 Web site: www.redcrossblood.org/hospitals/immunohematology E LEC T R ONI C P UBLISHE R Copyright 2017 by The American National Red Cross Paul Duquette ISSN 0894-203X O N O U R C OVE R The late 19th century and early 20th century Italian Jewish painter, Amedeo Modigliani, fits as well as anyone the romantic archetype of the tragic Bohemian artist. A master of expressionist portraits and figure studies, he enjoyed little success during his brief career. Elegantly lengthened mask-like faces and bodies with simplified idealized features were hallmarks of his style, although he also provoked controversy by his stark inclusion of pubic hair in his nudes. Impoverished and suffering from terminal tuberculosis in his early thirties, he sank deeper into alcoholism although he continued to paint. He had one serious romantic interest, Jeanne Hébuterne, a young model who became his fiancé at the end of his life, despite the objections of her parents. Here he depicts her during her pregnancy in a white chemise (1919). The article by Marchese addressing Lewis antibodies in pregnancy is included in this issue. David Moolten, MD CASE R EPO R T ABO serology in a case of persistent weak A in a recipient following a group O–matched unrelated bone marrow transplant D.E. Grey, E.A. Fong, C. Cole, J. Jensen, and J. Finlayson HLA-matched hematopoietic stem cell transplantation (HSCT) group to donor blood group in the recipient. In contrast, most from red blood cell (RBC)-incompatible donors is not uncommon. non-hematopoietic tissues retain expression of the patient’s The engraftment process following ABO-incompatible allogeneic original blood group for life, and these antigens may adsorb HSCT results in the transition from patient blood group to donor 5 blood group in the recipient. In contrast, most non-hematopoietic from the plasma onto the donor-derived RBCs. tissues retain expression of the patient’s original blood group for The correct serologic interpretation of the recipient’s life, and these antigens may adsorb from the plasma onto the ABO blood group during this engraftment process can be donor-derived RBCs. Correct serologic interpretation of the ABO blood group during this engraftment process can be difficult. difficult because of serologic discrepancies caused by ABO We present the serologic findings of a 15-year-old girl of Maori incompatibility between the recipient and donor during descent, who was diagnosed with acute myeloid leukemia and engraftment, transfusion of blood components with differing transplanted with an HLA-matched unrelated group O, D+ bone ABO group to the recipient, administration of high-dose marrow. Despite engraftment, her RBCs showed persistence of weak A. This case report showcases the importance of awareness intravenous immunoglobulin producing elevated levels of ABO and correct serologic interpretation of weak persistence of isoagglutinins, engraftment failure, and relapse. In addition, recipient ABH substance on the patient’s RBCs for clinical adsorption of recipient antigens onto donor RBCs adds another decision-making, blood component support, and patient well- level of complexity to the interpretation of the ABO group, and being. Immunohematology 2017;33:99–104. this may have implications for blood component support and Key Words: ABO, transplant, serology, monoclonal, clinical decision-making. antibody, recipient ABH substance We present the serologic findings of a case of persistent weak A in a recipient following a group O HLA-matched HLA-matched hematopoietic stem cell transplantation unrelated bone marrow transplant. (HSCT) from red blood cell (RBC)-incompatible donors is not uncommon.1 ABO-incompatible HSCT is of particular Case Report importance because of the consequences of acute hemolysis and the complexity of blood component selection. A 15-year-old girl of Maori descent was diagnosed with ABO antigens and the closely related H, secretor, and acute myeloid leukemia in 2014. Her RBCs typed as group A, Lewis histo-blood group carbohydrates are synthesized D+, Le(a–b–). A total of 46 units of group A, D+ RBCs and by specific glycosyltransferases encoded byABO, FUT1, 64 units of group A and 2 units of group O apheresis platelets FUT2, and FUT3, respectively. These enzymes incorporate were transfused during the first 5 months following diagnosis. monosaccharide units into precursor oligosaccharide chains, The patient was then transplanted with an HLA-matched modifying them and creating new antigenic specificities.2 unrelated group O, D+ bone marrow. A further 7 units of FUT1 and ABO encode enzymes that synthesize H, A, and B RBCs, all group O, D+, and 18 group A and 4 group O units in mesodermal and hematopoietic tissues that are therefore of apheresis platelets were transfused post-transplant, within intrinsic to the RBC. FUT2 and FUT3, together with ABO, are a 1-month period. There were no units of RBCs or platelets responsible for H, A, B, Lea, Leb, ALeb, and BLeb carbohydrates transfused during the following 27 months. on ectodermal tissues such as the gut, respiratory and urinary Engraftment was confirmed by day 24 post-transplant mucosae, and exocrine secretions, which are transported to with short tandem repeat chimerism studies (lymphocytes) the plasma and adsorbed onto the RBC membrane.2–4 showing 99 percent chimerism (Table 1). The engraftment process following ABO-incompatible Five months post-transplant, routine blood grouping allogeneic HSCT results in the transition from patient blood (BioVue column agglutination technology [CAT]; Ortho IMMUNOHEMATOLOGY, Volume 33, Number 3, 2017 99 D.E. Grey et al. Table 1. Results of patient ABO and D blood typing by CAT (BioVue, Ortho Clinical Diagnostics, Bridgend, UK; agglutination grade 0–4+) and short tandem repeat lymphocytes chimerism studies at diagnosis and at different time points post-transplant Anti-A Anti-B Anti-A,B Anti-D Anti-H A1 Cells B Cells STC (%) Time Point (MH04, 3D3) (NB10.5A5, NB1.19) (MH04, 3D3, NB10.5A5, NB1.19) At diagnosis 4+ 0 nt 4+ nt 0 4+ nt Day 9 mf 0 nt 4+ nt 0 3+ nt Day 24 nt nt nt nt nt nt nt 99 3 months nt nt nt nt nt nt nt 99 5 months 1+ 0 nt 4+ nt 0 3+ 99 8 months nt nt nt nt nt nt nt 98 Post-Transplant 9 months 2+ 0 nt 4+ nt 0 3+ nt 28 months 1+ 0 2+ 4+ 4+ 0 2+ nt mf = mixed field; nt = not tested; STC = short tandem repeat lymphocytes chimerism.
Recommended publications
  • Journal of Blood Group Serology and Molecular Genetics Volume 34, Number 1, 2018 CONTENTS
    Journal of Blood Group Serology and Molecular Genetics VOLUME 34, N UMBER 1, 2018 This issue of Immunohematology is supported by a contribution from Grifols Diagnostics Solutions, Inc. Dedicated to advancement and education in molecular and serologic immunohematology Immunohematology Journal of Blood Group Serology and Molecular Genetics Volume 34, Number 1, 2018 CONTENTS S EROLOGIC M ETHOD R EVIEW 1 Warm autoadsorption using ZZAP F.M. Tsimba-Chitsva, A. Caballero, and B. Svatora R EVIEW 4 Proceedings from the International Society of Blood Transfusion Working Party on Immunohaematology Workshop on the Clinical Significance of Red Blood Cell Alloantibodies, Friday, September 2, 2016, Dubai A brief overview of clinical significance of blood group antibodies M.J. Gandhi, D.M. Strong, B.I. Whitaker, and E. Petrisli C A S E R EPORT 7 Management of pregnancy sensitized with anti-Inb with monocyte monolayer assay and maternal blood donation R. Shree, K.K. Ma, L.S. Er and M. Delaney R EVIEW 11 Proceedings from the International Society of Blood Transfusion Working Party on Immunohaematology Workshop on the Clinical Significance of Red Blood Cell Alloantibodies, Friday, September 2, 2016, Dubai A review of in vitro methods to predict the clinical significance of red blood cell alloantibodies S.J. Nance S EROLOGIC M ETHOD R EVIEW 16 Recovery of autologous sickle cells by hypotonic wash E. Wilson, K. Kezeor, and M. Crosby TO THE E DITOR 19 The devil is in the details: retention of recipient group A type 5 years after a successful allogeneic bone marrow transplant from a group O donor L.L.W.
    [Show full text]
  • In Vitro Selection for Adhesion of Plasmodium Falciparum-Infected Erythrocytes to ABO Antigens Does Not Affect Pfemp1 and RIFIN
    www.nature.com/scientificreports OPEN In vitro selection for adhesion of Plasmodium falciparum‑infected erythrocytes to ABO antigens does not afect PfEMP1 and RIFIN expression William van der Puije1,2, Christian W. Wang 4, Srinidhi Sudharson 2, Casper Hempel 2, Rebecca W. Olsen 4, Nanna Dalgaard 4, Michael F. Ofori 1, Lars Hviid 3,4, Jørgen A. L. Kurtzhals 2,4 & Trine Staalsoe 2,4* Plasmodium falciparum causes the most severe form of malaria in humans. The adhesion of the infected erythrocytes (IEs) to endothelial receptors (sequestration) and to uninfected erythrocytes (rosetting) are considered major elements in the pathogenesis of the disease. Both sequestration and rosetting appear to involve particular members of several IE variant surface antigens (VSAs) as ligands, interacting with multiple vascular host receptors, including the ABO blood group antigens. In this study, we subjected genetically distinct P. falciparum parasites to in vitro selection for increased IE adhesion to ABO antigens in the absence of potentially confounding receptors. The selection resulted in IEs that adhered stronger to pure ABO antigens, to erythrocytes, and to various human cell lines than their unselected counterparts. However, selection did not result in marked qualitative changes in transcript levels of the genes encoding the best-described VSA families, PfEMP1 and RIFIN. Rather, overall transcription of both gene families tended to decline following selection. Furthermore, selection-induced increases in the adhesion to ABO occurred in the absence of marked changes in immune IgG recognition of IE surface antigens, generally assumed to target mainly VSAs. Our study sheds new light on our understanding of the processes and molecules involved in IE sequestration and rosetting.
    [Show full text]
  • Transfusion Medicine
    Transfusion Medicine Dr. Raymond SM Wong Department of Medicine & Therapeutics Prince of Wales Hospital The Chinese University of Hong Kong Content Blood groups Cross-matching and pre-transfusion tests Blood components and blood products Complications of blood transfusion Blood transfusion in specific situations Blood groups ( 血型) Determined by the red cell antigens ( 紅血球抗原) About 400 red blood cell group antigens have been described Individual who lack a particular blood group antigen may produce antibodies ( 抗體) reacting with that antigen and may lead to a transfusion reaction ( 輸血 反應) ABO and rhesus ( 獼因子) groups are the most clinically significant blood groups Blood group antibodies Naturally occurring antibodies occur in plasma of subjects who lack the corresponding antigen and who have not been transfused or been pregnant Most important are anti-A and anti-B Immune antibodies Develop in response to exposure to antigens by transfusion or by trans-placental passage during pregnancy Most important is the Rhesus (Rh) antibody, anti-D ABO blood group system Consists of 3 allelic genes: A, B and O A and B gene control the synthesis of specific enzymes which transform the H substance Ceramide glu gal gnac gal fuc H antigen galnac Ceramide glu gal gnac gal A antigen fuc gal Ceramide glu gal gnac gal B antigen fuc Cell membrane ABO blood group system Phenotype Genotype Naturally occurring (表型) (基因型) Antigens antibodies O OO O Anti-A, anti-B A AA or AO A Anti-B B BB or BO B Anti-A AB AB AB None The O gene is an amorph (無效基因)
    [Show full text]
  • The Incidence of Spontaneous Abortion in Mothers with Blood Group O Compared with Other Blood Types
    IJMCM Meta analysis Spring 2012, Vol 1, No 2 The incidence of spontaneous abortion in mothers with blood group O compared with other blood types ∗ Mohammad Hassanzadeh-Nazarabadi 1∗∗, Sahar Shekouhi 1, Najmeh Seif 1 Faculty of Medicince, Department of Medical Genetics, Mashhad University of Medical Sciences, Mashhad, Iran Although ABO incompatibility between mother and fetus has long been suspected as cause of spontaneous abortion in man, its precise contribution has not been completely resolved. In spite of reports in which the incompatible mating was recognized to be a cause of habitual abortion, and which eventually results in infertility or a reduction in the number of living children compared with the number in compatible matings, such effects were not observed in other studies. The aim of this review article was to show some evidence of relationship between ABO incompatibility and spontaneous abortion. Key words: spontaneous abortion, ABO blood group, incompatibility In 1900 Karl Landsteiner reported a series of discovered, attention was directed toward the tests, which identified the ABO blood group system. possibility of harmful effects when mother and This is the only blood group in which antibodies are fetus have different blood groups. As early as 1905 constantly, predictably, and naturally present in the A. Dienst suggested that toxemia of pregnancy serum of people who lack the antigen. ABO might be due to the transfusion of ABO- compatibility between mother and fetus is crucial (1). incompatible fetal blood into the mother. This was not substantiated, and the problem of ABO Downloaded from ijmcmed.org at 17:08 +0330 on Saturday September 25th 2021 Abortion interaction between mother and fetus was largely Spontaneous abortion also known as overshadowed by the more dramatic effects of Rh miscarriage, refers to a pregnancy that ends incompatibility leading to Rh hemolytic disease.
    [Show full text]
  • Glycophorins and the MNS Blood Group System: a Narrative Review
    16 Review Article Page 1 of 16 Glycophorins and the MNS blood group system: a narrative review Genghis H. Lopez1,2, Catherine A. Hyland1,3, Robert L. Flower1,3 1Clinical Services and Research Division, Australian Red Cross Lifeblood, Kelvin Grove, Queensland, Australia; 2School of Medical Science, Griffith Health, Griffith University, Gold Coast, Queensland, Australia; 3School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, Queensland, Australia Contributions: (I) Conception and design: All authors; (II) Administrative support: None; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: All authors; (V) Data analysis and interpretation: All authors; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Genghis H. Lopez, PhD. Clinical Services and Research Division, Australian Red Cross Lifeblood, 44 Musk Avenue, Kelvin Grove, Queensland 4059, Australia. Email: [email protected]. Abstract: The MNS blood group system, International Society of Blood Transfusion (ISBT) 002, is second after the ABO system. GYPA and GYPB genes encode MNS blood group antigens carried on glycophorin A (GPA), glycophorin B (GPB), or on variant glycophorins. A third gene, GYPE, produce glycophorin E (GPE) but is not expressed. MNS antigens arise from several genetic mechanisms. Single nucleotide variants (SNVs) contribute to the diversity of the MNS system. A new antigen SUMI (MNS50), p.Thr31Pro on GPA has been described in the Japanese population. Unequal crossing-over and gene conversion are the mechanisms forming hybrid glycophorins, usually from parent genes GYPA and GYPB. GYPE also contributes to gene recombination previously only described with GYPA. Recently, however, GYPE was shown to recombine with GYPB to form a GYP(B-E-B) hybrid.
    [Show full text]
  • ABO, Rh and Kell) and Ncovid-19 Susceptibility – a Retrospective Observational Study
    Relationship between blood group phenotypes (ABO, Rh and Kell) and nCOVID-19 susceptibility – A retrospective observational study. Sudhir Bhandari SMS Medical College and Hospitals, Jaipur, Rajasthan, India Ajeet Singh Shaktawat SMS Medical College and Hospitals, Jaipur, Rajasthan, India Amit Tak ( [email protected] ) SMS Medical College and Hospitals, Jaipur, Rajasthan, India https://orcid.org/0000-0003-2509-2311 Bhoopendra Patel Government Medical College, Barmer, Rajasthan, India Jyotsna Shukla SMS Medical College and Hospitals, Jaipur, Rajasthan, India Sanjay Singhal SMS Medical College and Hospitals, Jaipur, Rajasthan, India Kapil Gupta SMS Medical College and Hospitals, Jaipur, Rajasthan, India Jitendra Gupta SMS Medical College and Hospitals, Jaipur, Rajasthan, India Shivankan Kakkar SMS Medical College and Hospitals, Jaipur, Rajasthan, India Amitabh Dube SMS Medical College and Hospitals, Jaipur, Rajasthan, India Sunita Dia Medstar Washington Hospital Center, Washington DC 20010, USA. Mahendra Dia North Carolina State University, Raleigh, NC 27695-7609, USA. Todd C Wehner North Carolina State University, Raleigh, NC 27695-7609, USA. Research Article Keywords: ABO blood grouping, coronavirus disease, COVID-19, multinomial test Page 1/13 Posted Date: July 10th, 2020 DOI: https://doi.org/10.21203/rs.3.rs-39611/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 2/13 Abstract Since the outbreak of coronavirus disease-19 research has been continued to explore multiple facets of the disease. The objective of the present study is to evaluate the relationship between blood group phenotypes and COVID-19 susceptibility. In this hospital based, retrospective observational study 132 COVID-19 patients were enrolled from SMS Medical College and attached Hospitals, Jaipur, India after the proper approval from the institutional ethics committee.
    [Show full text]
  • Jo Shorthouse
    Jo Shorthouse Scientific Training Co-ordinator NHSBT Sheffield Scientific and Clinical Development To provide an overview of the following: Antigens and antibodies ABO blood group system Rh blood group system Other clinically significant blood group systems Scientific and Clinical Development Antigens are part of the surface of cells Red blood cells, white blood cells and platelets all have antigens Antibodies are protein molecules - called immunoglobulins (Ig) Usually of the immunoglobulin classes: IgG and IgM Found in the plasma Produced by the immune system following exposure to a foreign antigen Reactions to blood usually occurs when the antigen on the cells reacts with an antibody in the plasma Scientific and Clinical Development There are 30 known blood group systems Most clinically important are the ABO and Rh antigens Antigens in transfused blood can stimulate a patient to produce an antibody but only if the patient lacks the antigen themselves. The frequency of antibody production is very low but increases the more transfusions that are given Scientific and Clinical Development Blood transfusion i.e. blood carrying antigens foreign to the patient Pregnancy Foetal antigen entering maternal circulation during pregnancy or at birth stimulating antibody in mother Environmental factors (ie naturally acquired as with anti-A and anti-B) Scientific and Clinical Development IN VIVO (in the body) leads to the destruction of the cell either: directly when the cell breaks up in the blood stream (intravascular) indirectly where liver and
    [Show full text]
  • ABO and Rh Blood Group Systems / Compatibility Table Page 1 of 6
    BLOOD TRANSFUSION CLINICAL PRACTICE MANUAL ABO and Rh Blood Group Systems / Compatibility Table Page 1 of 6 ABO Blood Group System .............................................................................................................. 1 Rh (Rhesus) Blood Group System………….………………………………………….………………….. 2 Compatibility …………………………………………………………………………………………………. 3 ABO and Rh Compatibility Table ……………………………………………………………………….…. 4 Clinically Significant Blood Antibodies ………………………………………………………...………..… 5 ABO Blood Group System In the ABO blood group system, antigens A and B are either present or absent on the exterior of a person’s red blood cells (genetically determined). The name of an individual’s blood group corresponds to the antigen that is present on the exterior of his/her red blood cells. Antibodies are found in a person’s plasma. At approximately age 4 months, ABO antibodies have been naturally acquired to the antigen(s) that are absent from the exterior of the individual’s red blood cells. If the antigen (A or B) is absent from the exterior of a person’s red blood cells, the corresponding antibody will be found in the person’s plasma. If the antigen (A or B) is present on the exterior of a person’s red blood cells, corresponding antibody will not be found in the person’s plasma. Blood Group Antigen Antibody found on exterior of red blood cell found in plasma Group A A Anti-B Group B B Anti-A Group AB A and B none Group O none Anti-A and Anti-B ABO Blood Group System in Pictorial Format Legend: Antigen: found on exterior of red blood cell Antibody: found in plasma Date effective: Jan 2005 Date revised: August 2019 This is a controlled document.
    [Show full text]
  • Blood Group Compatibility
    BLOOD GROUP COMPATIBILITY Blood grouping identifies the ABO and Rh type of a recipient or donor. This grouping ensures that the patient receives compatible blood products. The ABO Blood Group System The ABO blood group is determined by the A or B antigen attached to the membrane of the red blood cell. Group A persons inherit the A antigen and make anti-B antibodies which destroy cells carrying B antigens. Group B persons inherit the B antigen and make anti-A antibodies which destroy cells carrying A antigens. Group AB persons inherit the A and B antigen and do not make either A or B “antibodies”. Group O persons do not inherit the A or B antigen and make “antibodies” which destroy cells carrying A or B antigens. Antibodies against A and B antigens are produced spontaneously in the plasma within the first few months of life. Blood Group Antigen on Red Cell Antibodies in Plasma A A antigen Anti-B B B antigen Anti-A AB both A & B antigens neither Anti-A or Anti-B O neither A & B antigens Anti-A and Anti-B Rhesus (Rh) Blood Group System The Rh type is determined by the presence or absence of the Rh “D” antigen on the red cells. • Rh positive – D antigen is present • Rh negative – D antigen is absent Unlike the ABO system, there are no naturally occurring Rh antibodies. Anti-D is produced when an Rh negative individual is exposed to Rh positive red cells (e.g. through transfusion or pregnancy). Rh antigens are carried on red cells only.
    [Show full text]
  • Prevalence of ABO, Rhd and Other Clinically Significant Blood Group Antigens Among Blood Donors at Tertiary Care Center, Gwalior
    ORIGINAL ARTICLE Bali Medical Journal (Bali Med J) 2020, Volume 9, Number 2: 437-443 P-ISSN.2089-1180, E-ISSN.2302-2914 Prevalence of ABO, RhD and other clinically ORIGINAL ARTICLE significant Blood Group Antigens among blood donors at tertiary care center, Gwalior Published by DiscoverSys CrossMark Doi: http://dx.doi.org/10.15562/bmj.v9i2.1779 Shelendra Sharma, Dharmesh Chandra Sharma,* Sunita Rai, Anita Arya, Reena Jain, Dilpreet Kaur, Bharat Jain Volume No.: 9 ABSTRACT Issue: 2 Background: Among all blood group systems and antigens, ABO and of them 1000 randomly selected donor samples were processed for D antigens of the Rh blood group system are of primary importance, complete Rh, Kell, Duffy and Kidd blood grouping. hence included in routine blood grouping and transfusion. Other blood Result: ABO group pattern was; A - 22.56%, B - 36.52%, AB - 9.8% group systems and antigens that are important in multiparous women, and O -31.12 %, while RhD status was RhD+ 90.99% and RhD- 9.01%. First page No.: 437 multi-transfused patients and hemolytic disease of newborn are Kell, Prevalence of Rh phenotypes was DCCee 43%, DCcee 33%, DCcEe 10%, Rh, Duffy, and Kidd. dccee 6.5%, DccEe 4.5%, Dccee 1%, DCCEe 0.3% and dccEe 0.2%. Aims and Objectives: To know the pattern of ABO, RhD and other Kell phenotype was K-k+ 95.5%, K+k+ 4.5%, while K+ k- and K- clinically significant major antigens of Rh, Kell, Duffy and Kidd blood k- phenotypes were not encountered in this study. Duffy phenotypes P-ISSN.2089-1180 group systems as well as evaluation of phenotypes, genotypes and were Fya+ Fyb+ 47.5%, Fya+ Fyb- 35%, Fya- Fyb+17% and Fya- Fyb- gene frequency of related antigens among blood donors in Gwalior 0.5%.
    [Show full text]
  • Recognizing and Resolving ABO Discrepancies
    R EVIEW Recognizing and resolving ABO discrepancies G.M. Meny Patient samples are routinely typed for ABO prior to transfusion. Table 1. Expected testing results of ABO blood groups Determining the ABO group requires both red blood cell (RBC) Patient RBCs and Patient plasma and antigen typing for A and B (forward type) and testing for anti-A Patient blood group Anti-A Anti-B A RBCs B RBCs and anti-B in the plasma (reverse type). An ABO discrepancy 1 exists when the result of an ABO RBC typing, or forward O – – + + type, does not agree with the result of the plasma typing, or A + – – + reverse type. This brief review examines several causes of ABO B – + + – discrepancies encountered in the clinical transfusion service. Options for resolving these discrepancies are presented, including AB + + – – a discussion of which discrepancies should be resolved using RBCs = red blood cells. molecular testing. Finally, case studies illustrate transfusion options in patients with ABO discrepancies. Discrepancies can will be presented, including a discussion of which discrepancies also be encountered when ABO typing is performed on samples from blood or tissue donors, although those discrepancies should be resolved using molecular testing. Finally, case studies will not be discussed in this review. Immunohematology are provided to illustrate transfusion options in patients with 2017;33:76–81. ABO discrepancies. Discrepancies can also be encountered when ABO typing is performed on samples from blood or Key Words: ABO blood group, ABO discrepancies, serologic tissue donors, but those discrepancies will not be discussed. typing, transfusion service ABO Discrepancy Resolution: General Approach The ABO blood group system was first described in 1900 by Landsteiner when agglutination was noted after mixing red An ABO discrepancy exists when the result of an ABO blood cells (RBCs) and sera together from several individuals.1 RBC typing, or forward type, does not agree with the result of Landsteiner initially named the groups “A,” “B,” and “C” based the plasma typing, or reverse type.
    [Show full text]
  • Genetic Characterisation of Human ABO Blood Group Variants with a Focus on Subgroups and Hybrid Alleles Hosseini Maaf, Bahram
    Genetic Characterisation of Human ABO Blood Group Variants with a Focus on Subgroups and Hybrid Alleles Hosseini Maaf, Bahram 2007 Link to publication Citation for published version (APA): Hosseini Maaf, B. (2007). Genetic Characterisation of Human ABO Blood Group Variants with a Focus on Subgroups and Hybrid Alleles. Division of Hematology and Transfusion Medicine, Department of Laboratory Medicine, Lund University. Total number of authors: 1 General rights Unless other specific re-use rights are stated the following general rights apply: Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal Read more about Creative commons licenses: https://creativecommons.org/licenses/ Take down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. LUND UNIVERSITY PO Box 117 221 00 Lund +46 46-222 00 00 Genetic Characterisation of Human ABO Blood Group Variants with a Focus on Subgroups and Hybrid
    [Show full text]